Navigation Links
Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma
Date:6/2/2011

EXTON, Pa., June 2, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, phase II study of MORAb-004 for the treatment of metastatic melanoma. The study will evaluate MORAb-004, a potentially first-in-class monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1), as a single agent therapy comparing its safety and therapeutic activity at two dosages.

The trial is designed as an open-label study to assess the efficacy of single agent MORAb-004 at one of two doses as determined by progression-free survival in patients with metastatic melanoma. Secondary objectives include assessment of an overall survival benefit, identification of an optimal dose, identification of biomarkers to predict efficacy, and safety of single agent MORAb-004. The patient population includes individuals with metastatic melanoma who have received at least one previous drug regimen.  It is estimated that nearly all metastatic melanoma tumors are endosialin/TEM-1 positive.(1)

Morphotek expects to enroll up to 80 patients in this study, which is being conducted at clinical centers in the United States, Europe and Australia.  As part of the trial, patient tumors will be tested for endosialin/TEM-1 and/or proteins within its pathway to determine if the pattern of expression relates to or determines clinical effect.

"We are excited to have initiated this phase II study of MORAb-004 in melanoma," stated Christina Coughlin, M.D., Ph.D. Senior Director of Clinical Development at Morphotek. "New agents are needed for the treatment of metastatic melanoma which remains an area of significant unmet medical need in the field of oncology. We are pleased to have the opportunity to collaborate with several of the world's experts in this disease setting."

MORAb-004 is a humanized monoclonal antibody specific for endosialin/TEM-1 protein.  The target is found t
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morphotek®, Inc. Receives Beacon Award From CancerCare
2. Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues
3. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
4. Regal One Announces Dividend of Rampart Detection Systems Common Stock
5. PharmaNet Announces Tender Offer and Consent Solicitation
6. Biomatrica Announces the Appointment of Dr. James A. Robb as a Member of the Scientific Advisory Board
7. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
8. WaferGen Announces $30 Million Financing
9. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
10. Vermillion Announces Notice of Allowance for Alzheimer Patent
11. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Richmond, VA (PRWEB) November 21, 2014 ... businessman who understood the need to surround himself with ... visionary, CEO and entrepreneur, his friends often marveled at ... how he lived his life and -- even with ... cure for the Alzheimer’s disease that would ultimately take ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/22/2014)... 2014   , ... Officer zu KLOX    ... Financial Officer bestellt    KLOX ist ... jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... Offering a complete line of laboratory ... promotion . The Sartorius Entris Balance is the perfect ... and easy-to-maintain balance entry level balance. , The Entris ... to help customer’s bridge the gap between a basic ... very durable. Sartorius is the second biggest balance manufacturer ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2
... 20 percent of the world,s industrial production is based ... of chemical reactions by factors of billions. Oil, pharmaceuticals, ... Many are hoping to make current ... less pollution. Highly active and selective nanocatalysts, for example, ...
... (Nasdaq: MYL ) announced today that it will ... 3, 2011, at 8:30 a.m. ET, to review the company,s ... 31, 2011. Mylan will release its financial results on May ... to access the call is 800.479.9001 or 719.325.2146 for international ...
... April 20, 2011 In its first full year as a ... annual revenue by 55 percent over 2009 and grew Q4 revenue ... released today. Annual sales reached $5.4 million, up by ... million, up by $800,000 from the same quarter of 2009. ...
Cached Biology Technology:UCLA researchers now 1 step closer to controlled engineering of nanocatalysts 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 3
(Date:11/12/2014)... GARDENS, Fla. , Nov. 12, 2014 ... announced today that its U.are.U ® fingerprint readers ... bakery chain in Central Mexico . ... June 2014 to eliminate payroll issues caused by employees ... to installing the U.are.U fingerprint readers, Montparnasse relied on ...
(Date:11/7/2014)... 2014 Leading Biometric companies aim to ... revolutionizing online transactions.  Companies in focus today are: NXT-ID, Inc. ... BABA ), Google Inc. (NASDAQ: GOOG ), ... EBAY ) and MasterCard Inc. (NYSE: MA) ... a biometric authentication company focused on the growing mobile commerce ...
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... A new analysis has provided a comprehensive comparison of ... breast cancer are at high risk of recurrence beyond ... endocrine treatment. The promising new findings will likely ... whose cancer recurs more than five years after diagnosis, ...
... led by prominent breast cancer experts from Europe and ... prospects for targeted therapies, and brings opportunities of truly ... said at the 5th IMPAKT Breast Cancer Conference in ... ,translational, breast cancer research that is beginning to have ...
... healthy people have been bombarded by stories in the media ... vitamin D levels, and urging high doses of supplements to ... to diabetes. But new research from Johns Hopkins finds ... the top of the range suggested by the Institute of ...
Cached Biology News:Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer 2Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer 3Study opens new prospects for developing new targeted therapies for breast cancer 2Study opens new prospects for developing new targeted therapies for breast cancer 3Vitamin D: More may not be better 2
... includes protein separation by two-dimensional electrophoresis ... software package from Bio-Rad and protein ... order to meet customers requirements regarding ... and format of the results permanent ...
... more than doubles the benefits of high ... analysis cycles of the standard binary system ... tandem mode. Difficult separations are dramatically improved ... heartcut configurations, on-line sample preparation is fully ...
... with a molecular weight of 16 kDa. Leptin ... produced by adipocytes [1,2]. Leptin is thought to ... weight [1-3]. In the human, leptin levels are ... [4]. A relationship between serum leptin levels and ...
... to the gene supplied by a customer. Mutated ... of choice to obtain a library of the ... to a desired value within 1-20 mutations per ... can be restricted to a desired region of ...
Biology Products: